Emcure Pharmaceuticals (EMCURE) Q3 24/25 earnings summary

Executive summary

• Q3 FY25 revenue grew 18% year-over-year, with adjusted PAT up 36% and reported PAT at ₹156 crore, driven by strong international and domestic performance.

• The company is executing a five-year plan focused on industry-leading growth through in-house innovation, M&A, and in-licensing.

• Strategic focus areas include dermatology, ophthalmology, women's health, and expansion in chronic and acute segments.

• The Mantra subsidiary is fully integrated, and the Sanofi India cardiovascular portfolio is contributing to growth.

Financial highlights

• Q3 revenue from operations reached ₹1,963 crore, up 18% year-over-year; PAT was ₹156 crore, up 30.3% YoY.

• Domestic business grew 12% to ₹888 crore; international business rose 23% to ₹1,075 crore.

• Canada business grew 34% to ₹352 crore; emerging markets up 40% to ₹365 crore.

• Gross margin for the quarter was 60.1%, down from 62.7% year-over-year due to business mix.

• EBITDA grew 23% to ₹362 crore; EBITDA margin at 18.4% (up from 17.6% YoY).

Outlook and guidance

• FY25 revenue growth expected at 18-19%, slightly below earlier 20% guidance due to slower domestic growth.

• Margins for the year expected at 18.5-19% (excluding other income), below initial 20-21% guidance.

• Margin improvement of 300-400 basis points targeted over the next 3-4 years as new initiatives scale.

• Focus on enhancing organic growth and margins through new product launches and operating efficiencies.

• Europe growth to pick up to high single digits in FY26 as new product approvals come through.